688212 澳华内镜
已收盘 05-18 15:00:00
资讯
新帖
简况
每周股票复盘：澳华内镜（688212）2025年净利同比减少45.50%
证券之星 · 05-17 03:36
每周股票复盘：澳华内镜（688212）2025年净利同比减少45.50%
澳华内镜（688212）披露2025年年度股东会会议资料，5月13日股价下跌0.65%
证券之星 · 05-13
澳华内镜（688212）披露2025年年度股东会会议资料，5月13日股价下跌0.65%
每周股票复盘：澳华内镜（688212）上消化道内窥镜手术系统进创新审查
证券之星 · 05-10
每周股票复盘：澳华内镜（688212）上消化道内窥镜手术系统进创新审查
澳华内镜（688212）披露上消化道电子内窥镜手术控制系统进入创新医疗器械特别审查程序，5月7日股价上涨3.91%
证券之星 · 05-07
澳华内镜（688212）披露上消化道电子内窥镜手术控制系统进入创新医疗器械特别审查程序，5月7日股价上涨3.91%
澳华内镜（688212）2026年一季报简析：营收上升亏损收窄，盈利能力上升
证券之星 · 05-01
澳华内镜（688212）2026年一季报简析：营收上升亏损收窄，盈利能力上升
图解澳华内镜年报：第四季度单季净利润同比增长514.62%
证券之星 · 04-30
图解澳华内镜年报：第四季度单季净利润同比增长514.62%
转向半导体市场 估值27亿元的臻宝科技拿到IPO批文
中金财经 · 04-29
转向半导体市场 估值27亿元的臻宝科技拿到IPO批文
4月22日澳华内镜涨5.36%，富国精准医疗混合A基金重仓该股
证券之星 · 04-22
4月22日澳华内镜涨5.36%，富国精准医疗混合A基金重仓该股
每周股票复盘：澳华内镜（688212）ERCP手术机器人将启注册临床
证券之星 · 04-19
每周股票复盘：澳华内镜（688212）ERCP手术机器人将启注册临床
【私募调研记录】重阳投资调研中际联合、澳华内镜
证券之星 · 04-16
【私募调研记录】重阳投资调研中际联合、澳华内镜
股市必读：澳华内镜（688212）今年截至4月15日累计跌幅已超20%
证券之星 · 04-16
股市必读：澳华内镜（688212）今年截至4月15日累计跌幅已超20%
澳华内镜：4月14日接受机构调研，嘉实基金、中欧基金等多家机构参与
证券之星 · 04-15
澳华内镜：4月14日接受机构调研，嘉实基金、中欧基金等多家机构参与
3月10日澳华内镜涨5.28%，富国精准医疗混合A基金重仓该股
证券之星 · 03-10
3月10日澳华内镜涨5.28%，富国精准医疗混合A基金重仓该股
每周股票复盘：澳华内镜（688212）2025年净利降45.45%
证券之星 · 03-01
每周股票复盘：澳华内镜（688212）2025年净利降45.45%
出海“广撒网”，伤了澳华内镜毛利率
新京报 · 02-27
出海“广撒网”，伤了澳华内镜毛利率
澳华内镜（688212）披露2025年度业绩快报，2月26日股价上涨0.38%
证券之星 · 02-26
澳华内镜（688212）披露2025年度业绩快报，2月26日股价上涨0.38%
澳华内镜(688212.SH)2025年度归母净利润1146.19万元，减少45.45%
智通财经 · 02-26
澳华内镜(688212.SH)2025年度归母净利润1146.19万元，减少45.45%
2月2日澳华内镜跌5.34%，富国精准医疗混合A基金重仓该股
证券之星 · 02-02
2月2日澳华内镜跌5.34%，富国精准医疗混合A基金重仓该股
股市必读：澳华内镜（688212）预计2025年全年营业收入7.64亿元至7.74亿元
证券之星 · 01-30
股市必读：澳华内镜（688212）预计2025年全年营业收入7.64亿元至7.74亿元
澳华内镜(688212.SH)发预减，预计2025年度归母净利润同比下降44.89%到61.69%
智通财经 · 01-29
澳华内镜(688212.SH)发预减，预计2025年度归母净利润同比下降44.89%到61.69%
加载更多
公司概况
公司名称：
上海澳华内镜股份有限公司
所属行业：
专用设备制造业
上市日期：
2021-11-15
主营业务：
上海澳华内镜股份有限公司的主营业务是电子内窥镜设备及内窥镜诊疗手术耗材研发、生产和销售。公司的主要产品是电子消化内镜、耳鼻喉镜、支气管镜、内镜诊疗耗材。公司是国家级专精特新“小巨人”企业。
发行价格：
22.50
{"stockData":{"symbol":"688212","market":"SH","secType":"STK","nameCN":"澳华内镜","latestPrice":34.78,"timestamp":1779087600000,"preClose":35.78,"halted":0,"volume":3530009,"delay":0,"changeRate":-0.0279,"floatShares":135000000,"shares":135000000,"eps":0.1175,"marketStatus":"已收盘","change":-1,"latestTime":"05-18 15:00:00","open":35.89,"high":35.9,"low":33.9,"amount":122000000,"amplitude":0.0559,"askPrice":34.78,"askSize":14,"bidPrice":34.7,"bidSize":36,"shortable":0,"etf":0,"ttmEps":0.1175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":5,"adr":0,"adjPreClose":35.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779067800000,1779075000000],[1779080400000,1779087600000]],"highLimit":39.36,"lowLimit":32.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":134665250,"isCdr":false,"pbRate":3.64,"roa":"--","peRate":296,"roe":"--","epsLYR":0.09,"committee":0.13556,"marketValue":4684000000,"turnoverRate":0.0262,"status":1,"afterMarket":{"amount":327836.28,"volume":9426,"close":34.78,"buyVolume":1374,"sellVolume":0,"time":1779089637558,"indexStatus":"已收盘 05-18 15:30:00","preClose":35.78},"floatMarketCap":4684000000},"requestUrl":"/m/hq/s/688212","defaultTab":"news","newsList":[{"id":"2636490064","title":"每周股票复盘：澳华内镜（688212）2025年净利同比减少45.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636490064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636490064?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:36","pubTimestamp":1778960173,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，澳华内镜报收于35.78元，较上周的37.19元下跌3.79%。本周，澳华内镜5月13日盘中最高价报37.66元。5月15日盘中最低价报35.3元。澳华内镜当前最新总市值48.18亿元，在医疗器械板块市值排名78/129，在两市A股市值排名3606/5203。2025年公司实现营业收入77,386.58万元，同比增长3.24%；归属于母公司所有者的净利润1,145.19万元，同比减少45.50%。董事会建议2025年度不进行利润分配，未分配利润结转下一年度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635978560","title":"澳华内镜（688212）披露2025年年度股东会会议资料，5月13日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635978560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635978560?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:45","pubTimestamp":1778669104,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，澳华内镜报收于36.76元，较前一交易日下跌0.65%，最新总市值为49.5亿元。公司于近日披露《2025年年度股东会会议资料》。公告显示，上海澳华内镜股份有限公司召开2025年年度股东会，审议《2025年度董事会工作报告》《2025年年度报告全文及其摘要》《2025年度利润分配方案》等议案。2025年公司实现营业收入77,386.58万元，同比增长3.24%；归属于母公司所有者的净利润1,145.19万元，同比减少45.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300035046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634414767","title":"每周股票复盘：澳华内镜（688212）上消化道内窥镜手术系统进创新审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2634414767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634414767?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:55","pubTimestamp":1778352910,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，澳华内镜报收于37.19元，较上周的34.96元上涨6.38%。本周，澳华内镜5月8日盘中最高价报38.08元。本周关注点公司公告汇总：上消化道电子内窥镜手术控制系统进入国家创新医疗器械特别审查程序公司公告汇总上海澳华内镜股份有限公司自主研发的上消化道电子内窥镜手术控制系统获国家药品监督管理局医疗器械技术审评中心同意，进入创新医疗器械特别审查程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633112841","title":"澳华内镜（688212）披露上消化道电子内窥镜手术控制系统进入创新医疗器械特别审查程序，5月7日股价上涨3.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633112841","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633112841?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:50","pubTimestamp":1778147444,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，澳华内镜报收于36.95元，较前一交易日上涨3.91%，最新总市值为49.76亿元。该股当日开盘35.37元，最高37.21元，最低35.24元，成交额达1.03亿元，换手率为2.11%。近日，上海澳华内镜股份有限公司发布公告称，其自主研发的上消化道电子内窥镜手术控制系统获国家药品监督管理局医疗器械技术审评中心同意，进入创新医疗器械特别审查程序。进入特别审查程序有助于优先办理注册申报，缩短注册周期，加快上市进度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700030046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","159883","09996","BK1100","BK1583","BK1222","09997","BK1574","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632660483","title":"澳华内镜（688212）2026年一季报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2632660483","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632660483?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:47","pubTimestamp":1777589266,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期澳华内镜发布2026年一季报。截至本报告期末，公司营业总收入1.38亿元，同比上升11.13%，归母净利润-2443.33万元，同比上升15.14%。本报告期澳华内镜盈利能力上升，毛利率同比增幅7.94%，净利率同比增幅25.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100007217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631442545","title":"图解澳华内镜年报：第四季度单季净利润同比增长514.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631442545","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631442545?lang=zh_cn&edition=full","pubTime":"2026-04-30 01:00","pubTimestamp":1777482005,"startTime":"0","endTime":"0","summary":"证券之星消息，澳华内镜2025年年报显示，当年度公司主营收入7.74亿元，同比上升3.24%；归母净利润1145.19万元，同比下降45.5%；扣非净利润-569.87万元，同比上升9.35%；其中2025年第四季度，公司单季度主营收入3.51亿元，同比上升41.06%；单季度归母净利润6754.44万元，同比上升514.62%；单季度扣非净利润6240.24万元，同比上升395.76%；负债率33.57%，投资收益21.82万元，财务费用320.96万元，毛利率65.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000003184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631591054","title":"转向半导体市场 估值27亿元的臻宝科技拿到IPO批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591054","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631591054?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:13","pubTimestamp":1777457585,"startTime":"0","endTime":"0","summary":"臻宝科技凭借“原材料+零部件+表面处理”一体化平台，在半导体核心零部件市场实现国产化突破，展现出强劲的成长性和行业竞争力。 近日， 专注于半导体设备精密零部件与表面处理服务的重庆臻宝科技股份有限公司，其科创板IPO注册获得证监会通过。作为国家级专精特新“小巨人”企业，臻宝科技凭借一体化业务平台，在半导体硅、石英等核心零部件细分市场已实现国产化突破。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/29/20260429216407.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/29/20260429216407.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260429/32189468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688233","BK4588","04335","688396","688409","688212","GFS","BK4585","688270","BK4535","000725","INTC","603458"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629644015","title":"4月22日澳华内镜涨5.36%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629644015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629644015?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:28","pubTimestamp":1776846509,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日澳华内镜涨5.36%，收盘报38.89元，换手率3.31%，成交量4.46万手，成交额1.73亿元。该股为医疗器械概念热股。重仓澳华内镜的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值3.1643，较上一交易日下跌1.25%，近一年上涨12.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628751387","title":"每周股票复盘：澳华内镜（688212）ERCP手术机器人将启注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2628751387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628751387?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:26","pubTimestamp":1776540368,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，澳华内镜报收于35.37元，较上周的36.05元下跌1.89%。机构调研要点问：公司ERCP手术机器人系统研发进展？答：2025年Q4公司ERCP手术机器人正式启动注册临床入组工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627259184","title":"【私募调研记录】重阳投资调研中际联合、澳华内镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2627259184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627259184?lang=zh_cn&edition=full","pubTime":"2026-04-16 08:08","pubTimestamp":1776298131,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月15日披露的机构调研信息，知名私募重阳投资近期对2家上市公司进行了调研，相关名单如下：1）中际联合 调研纪要：公司持续拓展海外市场，包括欧洲、美国及亚太市场，海外收入持续增长，毛利率高于境内，未来目标是外销收入占比达2/3。在投资方法上，重阳投资注重研究驱动的投资，强调严谨科学的投资流程在投资中的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026041600007292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","605305","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627231197","title":"股市必读：澳华内镜（688212）今年截至4月15日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627231197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627231197?lang=zh_cn&edition=full","pubTime":"2026-04-16 01:31","pubTimestamp":1776274268,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，澳华内镜报收于34.65元，下跌2.26%，换手率1.66%，成交量2.23万手，成交额7806.24万元。当日关注点来自交易信息汇总：澳华内镜股价连续3日下跌，当日跌2.26%，报34.65元，年内累计跌幅达20.52%。来自机构调研要点：公司ERCP手术机器人已于2025年Q4启动注册临床入组，预计2027-2028年有望上市。该股已连续3日下跌，当年累计跌幅20.52%。前10个交易日主力资金累计净流出628.62万元，股价累计下跌7.04%；融资余额累计增加780.73万元，融券余量累计增加4300股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600002174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627415281","title":"澳华内镜：4月14日接受机构调研，嘉实基金、中欧基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415281?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:02","pubTimestamp":1776254569,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月15日澳华内镜发布公告称公司于2026年4月14日接受机构调研，嘉实基金、中欧基金、华夏基金、国投瑞银、天弘基金、日兴证券、中信证券、重阳投资、敦和资本、华创证券、东财证券、南方基金、国投证券、国盛证券、东北证券、开源证券、申万宏源、华泰证券、西部证券、天风证券、广发资管、中泰证券、广发基金、工银瑞信基金、国泰基金、前海开源、博时基金参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500038813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618798050","title":"3月10日澳华内镜涨5.28%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618798050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618798050?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:20","pubTimestamp":1773130858,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日澳华内镜涨5.28%，收盘报41.04元，换手率1.88%，成交量2.53万手，成交额1.03亿元。重仓澳华内镜的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值2.8444，较上一交易日下跌1.51%，近一年上涨16.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616845995","title":"每周股票复盘：澳华内镜（688212）2025年净利降45.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616845995","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616845995?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:50","pubTimestamp":1772304618,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，澳华内镜报收于43.49元，较上周的42.27元上涨2.89%。本周关注点来自业绩披露要点：澳华内镜2025年归属净利润同比减少45.45%。来自公司公告汇总：营业利润同比下降83.51%，因销售结构变化致毛利率下滑。业绩变动主要因销售结构变化致毛利率下滑，叠加高研发投入及市场投入所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614868460","title":"出海“广撒网”，伤了澳华内镜毛利率","url":"https://stock-news.laohu8.com/highlight/detail?id=2614868460","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614868460?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:36","pubTimestamp":1772206560,"startTime":"0","endTime":"0","summary":"2025年，澳华内镜仍未走出业绩阵痛期。连续两年业绩下滑，去年归母净利润同比腰斩2月26日晚间，澳华内镜发布2025年业绩快报。然而，受此前医院设备采购需求阶段性收缩及行业去库存等因素影响，澳华内镜已连续两年面临业绩下滑压力。澳华内镜近三年营收结构及业务毛利率表现。2025年第三季度报告发布后，澳华内镜曾表示，报告期内公司毛利率有所下滑，核心原因是产品结构发生变化。共同作用最终导致整体毛利率出现下滑。","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2026/02/27/5691488703885682746.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/02/27/5691488703885682746.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1772202331129539.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1772202331129539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614006028","title":"澳华内镜（688212）披露2025年度业绩快报，2月26日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614006028","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614006028?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:38","pubTimestamp":1772116697,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，澳华内镜报收于42.71元，较前一交易日上涨0.38%，最新总市值为57.52亿元。该股当日开盘42.4元，最高43.05元，最低42.28元，成交额达6468.47万元，换手率为1.13%。近日，上海澳华内镜股份有限公司发布2025年度业绩快报，营业总收入77,353.71万元，同比增长3.20%；营业利润116.17万元，同比下降83.51%；归属于母公司所有者的净利润1,146.19万元，同比下降45.45%。业绩变动主要因销售结构变化致毛利率下滑，叠加高研发投入及市场投入所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614183740","title":"澳华内镜(688212.SH)2025年度归母净利润1146.19万元，减少45.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614183740","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614183740?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:13","pubTimestamp":1772093621,"startTime":"0","endTime":"0","summary":"智通财经APP讯，澳华内镜 披露2025年度业绩快报，公司实现营业收入7.74亿元，同比增长3.20%;实现归属于母公司所有者的净利润1146.19万元，同比减少45.45%;实现归属于母公司所有者的扣除非经常性损益的净亏损711.48万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"澳华内镜(688212.SH)2025年度归母净利润1146.19万元，减少45.45%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608350851","title":"2月2日澳华内镜跌5.34%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608350851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608350851?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:42","pubTimestamp":1770021744,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日澳华内镜跌5.34%，收盘报43.8元，换手率2.85%，成交量3.84万手，成交额1.71亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值2.987，较上一交易日上涨0.91%，近一年上涨35.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607058683","title":"股市必读：澳华内镜（688212）预计2025年全年营业收入7.64亿元至7.74亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607058683","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607058683?lang=zh_cn&edition=full","pubTime":"2026-01-30 02:38","pubTimestamp":1769711890,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，澳华内镜报收于42.15元，下跌0.31%，换手率1.14%，成交量1.54万手，成交额6497.65万元。业绩披露要点业绩预告澳华内镜发布业绩预告，预计2025年全年营业收入7.64亿元至7.74亿元。公司公告汇总2025年年度业绩预告上海澳华内镜股份有限公司预计2025年度实现营业收入76,431万元到77,439万元，同比增长1.97%到3.31%；归属于母公司所有者的净利润为805万元到1,158万元，同比下降44.89%到61.69%；扣除非经常性损益后的净利润为-1,053万元到-700万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000001515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607924081","title":"澳华内镜(688212.SH)发预减，预计2025年度归母净利润同比下降44.89%到61.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607924081","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607924081?lang=zh_cn&edition=full","pubTime":"2026-01-29 19:59","pubTimestamp":1769687988,"startTime":"0","endTime":"0","summary":"智通财经APP讯，澳华内镜(688212.SH)发布公告，公司预计2025年度实现归属于母公司所有者的净利润为805万元到1158万元，与上年同期相比，将减少943.22万元到1,296.22万元，同比下降44.89%到61.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"澳华内镜(688212.SH)发预减，预计2025年度归母净利润同比下降44.89%到61.69%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779151619082,"stockEarnings":[{"period":"1week","weight":-0.045},{"period":"1month","weight":-0.0167},{"period":"3month","weight":-0.1772},{"period":"6month","weight":-0.2769},{"period":"1year","weight":-0.2666},{"period":"ytd","weight":-0.2043}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0198},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0468},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.041}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海澳华内镜股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"6675人(较上一季度增加14.47%)","perCapita":"20174股","listingDate":"2021-11-15","address":"上海市闵行区光中路133弄66号","registeredCapital":"13466万元","survey":" 上海澳华内镜股份有限公司的主营业务是电子内窥镜设备及内窥镜诊疗手术耗材研发、生产和销售。公司的主要产品是电子消化内镜、耳鼻喉镜、支气管镜、内镜诊疗耗材。公司是国家级专精特新“小巨人”企业。","listedPrice":22.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"澳华内镜(688212)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供澳华内镜(688212)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"澳华内镜,688212,澳华内镜股票,澳华内镜股票老虎,澳华内镜股票老虎国际,澳华内镜行情,澳华内镜股票行情,澳华内镜股价,澳华内镜股市,澳华内镜股票价格,澳华内镜股票交易,澳华内镜股票购买,澳华内镜股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"澳华内镜(688212)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供澳华内镜(688212)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}